Synthesis, Pharmacological and Structural Characterization, and Thermodynamic Aspects of GluA2-Positive Allosteric Modulators with a 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-Dioxide Scaffold
摘要:
Positive allosteric modulators of ionotropic glutamate receptors are potential compounds for treatment of cognitive disorders, e.g., Alzheimer's disease. The modulators bind within the dimer interface of the ligand-binding domain (LBD) and stabilize the agonist-bound conformation, thereby slowing receptor desensitization and/or deactivation. Here we describe the synthesis and pharmacological testing at GluA2 of a new generation of 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides. The most potent modulator 3 in complex with GluA2-LBD-L483Y-N754S was subjected to structural analysis by X-ray crystallography, and the thermodynamics of binding was studied by isothermal titration calorimetry. Compound 3 binds to GluA2-LBD-L483Y-N754S with a K-d of 0.35 mu M (Delta H = -7.5 kcal/mol and -T Delta S = -1.3 kcal/mol). This is the first time that submicromolar binding affinity has been achieved for this type of positive allosteric modulator. The major structural factor increasing the binding affinity of 3 seems to be interactions between the cyclopropyl group of 3 and the backbone of Phe495 and Met496.
Synthesis and Biological Evaluation of 4-Chloro-3,5-dinitrobenzotrifluoride Analogues as Antileishmanial Agents
摘要:
Desnitro analogues of 4-chloro-3,5-dinitrobenzotrifluoride (chloralin) (2), an in vitro microtubule inhibitor of several Leishmania species, have been synthesized from 2-halo-5-(trifluoromethyl)benzenesulfonyl chlorides 4 and 5. The analogues exhibited moderate to excellent activity when tested against Leishmania donovani amastigotes in vitro. Two representative compounds, 7f and 8, were tested against the Khartoum strain of L. donovani in a hamster model using chloralin (2) and Glucantime (one of the current therapeutics of choice in the treatment of Leishmania) as standards, the results of which will be discussed herein.
Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them
申请人:FRANCOTTE Pierre
公开号:US20100009974A1
公开(公告)日:2010-01-14
Compounds of formula (I):
wherein:
R
Cy
represents an unsubstituted or substituted cycloalkyl group or cycloalkylalkyl group,
R
1
, R
2
, R
3
and R
4
, which may be the same or different, each represent a hydrogen or halogen atom or a nitro group; a cyano group; a hydroxy group; an alkoxy group; an alkyl group; an unsubstituted or substituted amino group; a carboxy group; an alkoxycarbonyl group; an aryloxycarbonyl group; an unsubstituted or substituted aminocarbonyl group.
Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator.
Polymers containing grafted bis(sulfonyl)imide sodium or lithium salts, methods for production thereof and uses of same as electrolytes for batteries
申请人:CDP INNOVATION
公开号:US10141603B2
公开(公告)日:2018-11-27
The invention relates to novel polymers containing grafted sodium or lithium bis(sulfonyl)imides, to the methods for the production thereof, and to the uses of same as electrolytes in batteries.
本发明涉及含有接枝钠或锂双(磺酰基)亚胺的新型聚合物、其生产方法以及用作电池电解质的用途。
Discovery of XEN445: A potent and selective endothelial lipase inhibitor raises plasma HDL-cholesterol concentration in mice
作者:Shaoyi Sun、Richard Dean、Qi Jia、Alla Zenova、Jing Zhong、Celene Grayson、Clark Xie、Andrea Lindgren、Pritpaul Samra、Luis Sojo、Margaret van Heek、Linus Lin、David Percival、Jian-min Fu、Michael D. Winther、Zaihui Zhang
DOI:10.1016/j.bmc.2013.10.023
日期:2013.12
Endothelial lipase (EL) activity has been implicated in HDL metabolism and in atherosclerotic plaque development; inhibitors are proposed to be efficacious in the treatment of dyslipidemia related cardiovascular disease. We describe here the discovery of a novel class of anthranilic acids EL inhibitors. XEN445 (compound 13) was identified as a potent and selective EL inhibitor, that showed good ADME and PK properties, and demonstrated in vivo efficacy in raising plasma HDLc concentrations in mice. (C) 2013 Elsevier Ltd. All rights reserved.
Nouveaux dérivés de benzothiadiazines cycloalkylées, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
申请人:Les Laboratoires Servier
公开号:EP2147915B1
公开(公告)日:2010-09-15
NOUVEAUX POLYMERES CONTENANT DES SELS DE LITHIUM OU DE SODIUM DE BIS(SULFONYL)IMIDES GREFFES, LEURS PROCEDES DE PREPARATION ET LEURS UTILISATIONS COMME ELECTROLYTES POUR BATTERIES